Summit Therapeutics Inc. Increase (Decrease) in Other Current Assets
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Other Current Assets of -$558.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2022-11-09
- Summit Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2022-09-30 was -$1.94M, a 800.72% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2022-06-30 was $1.01M, a 186.16% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2022-03-31 was $370.00K.
- Summit Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2021-09-30 was $277.00K, a 20.40% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in other current assets for fiscal 2020 was $24.00K.
- Summit Therapeutics Inc. increase (decrease) in other current assets for fiscal 2019 was -$580.00K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 11 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|---|
| 2022-09-30 | -$1.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$928.00K derived: sum of 2 quarters · filed 2022-11-09 | -$558.00K 10-Q · filed 2022-11-09 | ||
| 2022-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.38M 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $370.00K 10-Q · filed 2022-05-11 | ||||
| 2021-09-30 | $277.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $631.00K derived: sum of 2 quarters · filed 2022-11-09 | $82.00K 10-Q · filed 2022-11-09 | -$188.00K derived: sum of 4 quarters · filed 2022-11-09 | |
| 2021-06-30 | $354.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$195.00K 10-Q · filed 2022-08-11 | -$465.00K derived: sum of 3 quarters · filed 2022-08-11 | -$117.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$549.00K 10-Q · filed 2022-05-11 | -$819.00K derived: sum of 2 quarters · filed 2022-05-11 | -$471.00K derived: sum of 3 quarters · filed 2022-05-11 | -$492.00K derived: sum of 4 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$270.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | $78.00K derived: sum of 2 quarters · filed 2021-11-15 | $57.00K derived: sum of 3 quarters · filed 2021-11-15 | $24.00K 10-K · filed 2021-03-31 | |
| 2020-09-30 | $348.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $327.00K derived: sum of 2 quarters · filed 2021-11-15 | $294.00K 10-Q · filed 2021-11-15 | ||
| 2020-06-30 | -$21.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$54.00K 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | -$33.00K 10-Q · filed 2021-05-17 | ||||
| 2019-12-31 | -$492.00K 10-K · filed 2021-03-31 | ||||
| 2019-09-30 | -$641.00K derived: 10-Q 9 month − 8-K 6 month · filed 2020-11-16 | -$641.00K 10-Q · filed 2020-11-16 | |||
| 2019-06-30 | $0.00 8-K · filed 2020-09-29 | ||||
| 2019-01-31 | -$580.00K 10-K · filed 2021-03-31 | ||||
| 2018-01-31 | $2.04M 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |